Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking

Annals of Surgical Oncology

Volumn 13, Issue 12, 2006, Pages 1711-1716

  Le, Tien ^a   Alshaikh, Ghadeer ^a   Hopkins, Laura ^a   Faught, Wylam ^b   Fung, Michael Fung Kee ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b ROYAL ALEXANDRA HOSPITAL   (Canada)

Author keywords

Neoadjuvant chemotherapy; Ovarian cancer; Postoperative morbidities; Prognosis

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER RISK; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LOG RANK TEST; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; POSTOPERATIVE COMPLICATION; PREDICTOR VARIABLE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL DISTRIBUTION; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, ENDOMETRIOID; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33845622468     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9125-6     Document Type: Article

References (24)

1. National Cancer Institute of Canada. Canadian Cancer Statistics 2005. Toronto: Canadian Cancer Society; National Cancer Institute of Canada; Statistics Canada; Provincial/Territorial Cancer Registries; Health Canada, 2005.
2. Omura GA, Brady MF, Homseley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9:1138-50.
3. Van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME, et al. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989; 7:769-73.
4. Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993; 71(4 Suppl):1534-40.
5. Van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction. Gynecological Cancer Cooperative Group of European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332:629-34.
6. Brown JV, Karlan BY, Greenspoon JS, et al. Periprative coagulopathy in patients undergoing primary cytoreduction. Cancer 1993; 71:2557-61.
7. Buchsbaum HJ, Brady MF, Delgado G, et al. Surgical staging of ovarian carcinoma. Surg Gynecol Obstet 1989; 169:226-32.
8. Chen SS, Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian cavinoma. Gynecol Oncol 1985; 10:190-7.
9. Deppe G, Malviya VK, Malone JM Jr, et al. Debulking of pelvic and para-aortic lymph node metastases in ovarian cancer with Cavitron ultrasonic surgical aspirator. Obstet Gynecol 1990; 76:1140-2.
10. Eisenkop SM, Spirtos NM, Montag TW, et al. The impact of subspecialty on the management of advanced ovarian carcinoma. Gynecol Oncol 1992; 47:203-9.
11. Guidozzi F, Ball JHS. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994; 53:326-30.
12. Schwarz GF, Meltzer AJ. Breast conservation after neoadjuvent chemotherapy for stage II carcinoma of the breast. Am Coll Surg 2005; 201:327-34.
13. Singletary SE. Breast cancer: the value of preoperative chemotherapy. Am J Cancer 2002; 1:121-6.
14. Lam CW, Chen WT, Liu MT, Chang CS. Effects of preoperative concurrent chemotherapy in locally advanced low rectal cancer after radical resection surgery. Int Surg 2005; 90:53-9.
15. Nudelman IL, Fuko V, Geller A. Treatment or rectal cancer by chemoradiation followed by surgery: analysis and early clinical outcome in 66 patients. Isr Med Assoc J 2005; 7:377-80.
16. De Paoli A, Innocente R, Buonadonna A. Neoadjuvant therapy of rectal cancer new treatment perspectives. Tumori 2004; 90:373-8.
17. Osti MF, Valeriani M, Masoni L. Neoadjuvent chemoradiation for locally advanced carcinoma of the rectum. Tumori 2004; 90:303-9.
18. Abbas A, Tunio MA, Ali N. Neoadjuvent chemoradiation in unresectable carcinoma of rectum. J Ayub Med Coll Abbottabad 2004; 16:24-9.
19. Santin AD, Bellone S, Parrish RS, et al. Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix. Gynecol Obstet Invest 2003; 56:28-34.
20. Brand A. Immunological aspects of blood transfusions. Transpl Immunol 2002; 10:183-90.
21. Blumberg N, Triulzi DJ, Heal JM. Transfusion-induced immunomodulation and its clinical consequences. Transfus Med Rev 1990; 4(4 Suppl 1):24-35.
22. Tartter PI, Burrows L, Papatestas AE, Lesnick G, Aufses AH Jr. Perioperative blood transfusion has prognostic significance for breast cancer. Surgery 1985; 97:225-30.
23. Craig SR, Adam DJ, Yap PL, et al. Effect of blood transfusion on survival after esophagogastrectomy for carcinoma. Ann Thorac Surg 1998; 66:356-61.
24. Tartter PI, Burrows L, Kirschner P. Perioperative blood transfusion adversely affects prognosis after resection of Stage I (subset N0) non-oat cell lung cancer. J Thorac Cardiovasc Surg 1984; 88(5 Pt 1):659-62.